Review
Open access
Sep 2026
Current and Emerging Targeted Therapy in Advanced Gastroesophageal Adenocarcinoma
Novel targeted agents, particularly to HER2 and CLDN18.2, have demonstrated survival benefit despite ongoing challenges, and VEGFR2 inhibition with ramucirumab remains a cornerstone in later lines, while novel VEGF/PD-1(L1) bispecifics are under investigation.
O. Oakley, U. Mahmood, Yusuf Ahmad et al.
· Pharmaceuticals · 0 citations